Graham Capital Management L.P. Invests $498,000 in SI-BONE, Inc. (NASDAQ:SIBN)

Graham Capital Management L.P. purchased a new position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 35,487 shares of the company's stock, valued at approximately $498,000. Graham Capital Management L.P. owned 0.08% of SI-BONE at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. raised its stake in shares of SI-BONE by 8.9% during the 4th quarter. Invesco Ltd. now owns 17,203 shares of the company's stock worth $241,000 after purchasing an additional 1,413 shares during the period. Rhumbline Advisers raised its stake in SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock worth $808,000 after buying an additional 1,683 shares in the last quarter. Barclays PLC boosted its position in shares of SI-BONE by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after purchasing an additional 2,589 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of SI-BONE by 6.2% during the 4th quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock valued at $782,000 after buying an additional 3,250 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of SI-BONE by 11.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,742 shares of the company's stock worth $446,000 after acquiring an additional 3,318 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at SI-BONE

In related news, SVP Michael A. Pisetsky sold 3,128 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. This trade represents a 1.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Laura Francis sold 5,412 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $19.49, for a total value of $105,479.88. Following the completion of the transaction, the chief executive officer now directly owns 490,987 shares of the company's stock, valued at $9,569,336.63. The trade was a 1.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 92,565 shares of company stock valued at $1,669,871 in the last quarter. Corporate insiders own 4.00% of the company's stock.

SI-BONE Stock Down 1.9%

Shares of SIBN stock traded down $0.38 during trading hours on Wednesday, reaching $19.34. 41,790 shares of the company's stock were exchanged, compared to its average volume of 373,840. The company has a market cap of $823.96 million, a price-to-earnings ratio of -20.99 and a beta of 0.82. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The stock's 50 day moving average is $15.02 and its 200-day moving average is $15.11.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. Analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SIBN has been the subject of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial upped their price target on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.